Passez à l'illimité avec Magzter GOLD

Obtenez un accès illimité à plus de 9 000 magazines, journaux et articles Premium pour seulement

$149.99

$74.99/Année

Essayer OR - Gratuit

Passez à l'illimité avec Magzter GOLD

Obtenez un accès illimité à plus de 9 000 magazines, journaux et articles Premium pour seulement

$NaN

$NaN/Année

Dépêchez-vous, offre à durée limitée !

Heures

minutes

secondes

Bio Spectrum - BioSpectrum India May 2025

Passez à l'illimité avec Magzter GOLD

Lire Bio Spectrum avec plus de 9 000 autres magazines et journaux avec un seul abonnement

Voir le catalogue

1 mois

$14.99

1 an $149.99

$74.99

$6/month

Save 50%
Hurry, Offer Ends in 14 Days

(OR)

Abonnez-vous uniquement à Bio Spectrum

Cadeau Bio Spectrum

Annulez à tout moment.

(Aucun engagement) ⓘ

Si vous n'êtes pas satisfait de votre abonnement, vous pouvez nous contacter par e-mail à help@magzter.com dans les 7 jours suivant la date de début de l'abonnement pour obtenir un remboursement complet. Sans poser de questions, promis ! (Remarque : Non applicable aux achats à l'unité)

Abonnement numérique

Accès instantané ⓘ

Abonnez-vous maintenant pour commencer instantanément à lire sur le site Web de Magzter, les applications iOS Android et Amazon.

Vérifié Sécurisé

paiement ⓘ

Magzter est un marchand Stripe vérifié.

Dans ce numéro

Transformative Years of BIOSIMILARS 2025 marks 25 years since India first ventured into the biosimilar space. Over the past quarter century, the country has consistently solidified its position as a global leader in biosimilar approvals, with 135 approvals till January 2025. Initially focused on simpler biologics, the field now includes developing and approving complex monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), a diversified therapeutic focus, and a growing number of innovative players entering the field. As the industry celebrates this silver jubilee, we reflect on the journey that has not only transformed India's biotechnology sector but has also played a pivotal role in making life saving treatments more accessible and affordable worldwide.

Leveraging Genomic Data

While the entire pharma world is still grappling with the issue of tariffs by the US and its impact on the US consumers as well as various other countries (though there is 90-day relief on the issue), India has achieved a significant step in the healthcare and medicines sector.

2 mins

Health Ministry releases national guidelines on medical oxygen management

The Ministry of Health and Family Welfare, Government of India, has released the National Guidelines on Medical Oxygen Management at a workshop held at the All India Institute of Medical Sciences (AIIMS), Delhi.

1 mins

Ankura Hospitals secures Rs 165 Cr funding from ADB

Hyderabad-based Ankura Hospitals, a leading healthcare provider specialising in super-specialty tertiary and quaternary care services for women and children, has secured Rs 165 crore in funding from the Asian Development Bank (ADB).

1 mins

25 Transformative Years of BIOSIMILARS

BIOSIMILARS

6 mins

India's Biosimilars Revolution

The increasing incidence of chronic illnesses such as cancer, diabetes, and autoimmune disorders, which necessitate long-term biologic therapies, is driving the growth of the biosimilar market in India.

5 mins

"The biosimilar developers are eagerly awaiting revised CDSCO regulations that might lead to simplification of the development pathway for biosimilars"

How has India's biosimilars landscape evolved over the past 25 years, and what have been the most significant milestones?

4 mins

Ensuring Biotech Startup Success Stories

According to the Indian BioEconomy Report 2025, the number of biotech startups has more than doubled from 4237 in 2020 to 10,075 in 2024.

4 mins

Can technology uplift the Indian BioSuppliers ecosystem?

The bioindustrial and biopharma segment have emerged as the two key sectors contributing majorly (82 per cent) to India's bioeconomy which stands at $165.7 billion in 2024.

5 mins

"Evolving regulatory requirements, heightened scrutiny from regulatory agencies, and geopolitical uncertainties pose challenges"

Strides Pharma Science demerged its Contract Development and Manufacturing Organisation (CDMO) business into OneSource Specialty Pharma Ltd, following approval by the National Company Law Tribunal (NCLT) in 2024.

5 mins

"Govt initiatives and private sector investments are boosting adoption of NGS technologies for various applications"

Illumina, a global leader in DNA sequencing and array-based technologies, recently launched the MiSeq i100 and MiSeq i100 Plus Systems.

4 mins

Medical Device Classification and FDA Approva:What Startups Need to Know

For many innovators, the United States represents a key market, being the world’s largest for medical devices.

4 mins

Specialised Skill Development for GCCs in India

India is a key hub for Life Sciences and Healthcare (LSHC) Global Capability Centers (GCCs).

5 mins

Biomarkers in Kidney Health: Enhancing Early Detection and Treatments

Emerging biomarkers such as neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule-1 (KIM-1) have shown great potential in the early diagnosis of kidney injury.

4 mins

Unlocking Future of Large and Small Molecule Pharma R&D with Science-Driven Digital Solutions

As pharmaceutical companies expand their R&D operations globally, Indian Contract Development and Manufacturing Organisations (CDMOs) are attracting significant investment.

5 mins

BiomatiQ Inaugurates State-of-the-Art, Fully Automated Production Line for Ready-to-Use Culture Media

Hyderabad, India - BiomatiQ, a leading life science products distribution company, has marked a significant milestone with the inauguration of its state-of-the-art, fully automated production line for ready-to-use culture media.

4 mins

Nagaland University announces undergraduate programme in Basic Sciences

Nagaland University is launching anew undergraduate programme in Basic Sciences from the Academic Year 2025-26.

1 mins

Mushrooming Generics.Turn Affordable Lifeline

The Indian pharmaceutical market is witnessing a dramatic transformation following the patent expiry of Empagliflozin (sold under the brand name Jardiance by Boehringer Ingelheim) on March 11, 2025, used for treatment of adults with type 2 diabetes mellitus, as an adjunct to diet and exercise to improve glycemic control and to reduce the risk of cardiovascular death in patients with established cardiovascular disease.

2 mins

Lire toutes les histoires de Bio Spectrum

Bio Spectrum Description:

Éditeur: MM-Activ-Sci-Tech-Communication

Catégorie: Business

Langue: English

Fréquence: Monthly

India's leading publication that covers the business of bio-technology. With comprehensive analyses of policy issues, products and services across the bio-pharma, bio-informatics, bio-infrastructure and bio-agriculture segments, it is the industry's most authoritative source of information.